Literature DB >> 18693207

Severe constipation associated with extended-release bupropion therapy.

Jody L Lounsbery1, Mitchell A Medow, Christopher G Green.   

Abstract

PURPOSE: A case of bupropion-induced constipation is reported.
SUMMARY: A 38-year-old man went to a clinic with a chief complaint of depression. He was prescribed extended-release bupropion 150 mg orally daily. Three weeks later, the patient returned to the clinic for a follow-up visit regarding his depression. He reported that his depression symptoms improved, but he complained of constipation and inflamed hemorrhoids from straining with defecation. He used docusate sodium, fiber supplements, and Preparation H(Wyeth) products with some relief. The bupropion was continued for his depression. Recommendations were given to the patient to increase fluids, maintain fiber intake, and add exercise. One week later, the patient complained of rectal pain and minimal bleeding. Prescriptions were given to the patient for hydrocortisone suppositories and 2.5% cream to be used twice daily. Three days later, the patient returned to the clinic complaining of increased pain and no relief from the hydrocortisone suppositories and cream. The rectal examination showed 3- and 5-cm hemorrhoids, one of which was thrombotic. The patient was instructed to continue hydrocortisone products, increase fluids, and continue docusate. Hemorrhoidectomy surgery was eventually performed, as well as a fissurectomy. The patient discontinued bupropion on his own due to the constipation approximately one week before the surgery. The constipation resolved after discontinuation of bupropion.
CONCLUSION: Extended-release bupropion was the probable cause of severe constipation in a man with multiple medical problems.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18693207     DOI: 10.2146/ajhp070486

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  1 in total

1.  Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.

Authors:  W E Whitehead; K Duffy; J Sharpe; T Nabata; M Bruce
Journal:  Aliment Pharmacol Ther       Date:  2016-11-07       Impact factor: 8.171

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.